PDF (1054K)
摘要
目的: 对本中心 2018 年启动的低剂量糖皮质激素(glucocorticoid,GC)治疗孤立性风湿性多肌痛(polymyalgia rheumatica,PMR)的注册随机对照研究队列开展回顾性延长随访二次分析,探索临床缓解后 GC 减停及停药后复发情况。方法: 纳入 2018 年 1 月至 2023 年 12 月在本中心住院并完成长期随访的初治孤立性 PMR 患者共 86 例,中位随访时间为 19 个月[四分位间距(IQR)为 10.0~53.0 个月]。基于原始注册研究的分组方案分为三组:(1)GC 单药组 25 例;(2)GC 联合甲氨蝶呤 (methotrexate, MTX,10 mg/周)组 32 例;(3)GC 联合雷公藤多苷(tripterygium wilfordii polyglycosides,TW,20 mg,tid)组 29 例。三组患者 GC 起始剂量均为泼尼松 10 mg/d;与原随机对照研究预设标准化减量方案不同,本研究中患者达到临床缓解后结合临床症状与炎症指标个体化进行糖皮质激素逐步减量,后续以 GC 单药维持并继续递减。分析临床缓解后 GC 减量、停药后的疾病转归,探索停药后复发的潜在相关因素。结果: 三组患者经诱导治疗后均获得临床缓解。GC 单药组、GC+TW 组及 GC+MTX 组达到临床缓解的中位时间均为 6 个月(IQR 分别为 3.0~ 7.5 个月 、 3.0~ 7.5 个月和 3.0~8.8 个月),三组间差异无统计学意义。三组共有 47 例患者(54.7%)停用 GC,自获得临床缓解至完全停药的中位时间为 20.8 个月(IQR 为 14.9~36.5 个月)。GC 单药组、GC+TW 组和 GC+MTX 组的 GC 停药率分别为 64.0%、51.7% 和 50.0%,组间差异无统计学意义(P=0.532)。停用 GC 后随访,三组患者随访期内复发率分别为 0(0/16)、 20.0%(3/15)和 12.5%(2/16), 组间差异无统计学意义(P=0.181)。47 例停用 GC 患者中 5 例(10.6%)停药后复发,中位复发时间为 10.8 个月(范围 6~24 个月)。探索性分析提示复发患者基线中性粒细胞-淋巴细胞比值(neutrophil-to-lymphocyte ratio,NLR)高于未复发者(中位数 7.2 vs. 3.3,P=0.034)。结论: 孤立性 PMR 患者经糖皮质激素治疗获得临床缓解后,逐步减量甚至停药是可行的,但停药后存在复发风险。探索性结果提示基线 NLR 升高可能与 GC 停药后复发存在相关性;受限于本研究复发事件数较少,其预测价值尚需更大样本前瞻性队列进一步验证,暂不推荐直接用于临床风险分层。
Abstract
AIM: To retrospectively analyze the extended follow-up data from a registered randomized controlled trial initiated at our center in 2018 involving low-dose glucocorticoid (GC) treatment for isolated polymyalgia rheumatica (PMR), and to investigate GC tapering and discontinuation after clinical remission, as well as relapse following GC withdrawal. METHODS: A total of 86 treatment-naïve patients with isolated PMR who were hospitalized at our center between January 2018 and December 2023 and underwent long-term follow-up were included. The median follow-up duration was 19 months[interquartile range (IQR), 10.0-53.0 months]. According to the treatment allocation in the original registered trial, patients were divided into three groups: GC monotherapy (n=25), GC plus methotrexate (MTX, 10 mg/week; n=32), and GC plus Tripterygium wilfordii polyglycosides (TW, 20 mg three times daily; n=29). All patients received an initial prednisone dose of 10 mg/day. Different from the prespecified standardized tapering protocol in the original RCT, GC doses were gradually tapered on an individualized basis according to clinical symptoms and inflammatory markers after achieving clinical remission. Subsequently, all patients received GC monotherapy for maintenance and further tapering.GC tapering, discontinuation, and subsequent clinical outcomes were evaluated, and potential factors associated with relapse after GC withdrawal were explored. RESULTS: All patients in the three treatment groups achieved clinical remission following induction therapy. The median time to remission was 6 months in all three groups, with IQRs of 3.0-7.5, 3.0-7.5, and 3.0-8.8 months in the GC monotherapy, GC plus TW, and GC plus MTX groups, respectively, with no statistically significant difference among groups. Overall, 47 patients (54.7%) discontinued GC therapy. The median interval from clinical remission to complete GC discontinuation was 20.8 months (IQR, 14.9–36.5 months). The GC discontinuation rates were 64.0%, 51.7%, and 50.0% in the GC monotherapy, GC plus TW, and GC plus MTX groups, respectively, with no statistically significant difference (P= 0.532). Among patients who discontinued GC therapy, the relapse rates during follow-up were 0% (0/16), 20.0% (3/15), and 12.5% (2/16), respectively, with no statistically significant difference among groups (P=0.181). Of the 47 patients who discontinued GC therapy, 5 (10.6%) experienced relapse after withdrawal, with a median time to relapse of 10.8 months (range, 6-24 months). Exploratory analysis showed that baseline neutrophil-to-lymphocyte ratio (NLR) was higher in relapsed patients than non-relapsed patients (median, 7.2 vs. 3.3; P=0.034). CONCLUSION: Gradual GC tapering and eventual discontinuation are feasible in some patients with isolated PMR after achieving clinical remission, although relapse may occur following withdrawal. Exploratory findings suggest elevated baseline NLR may correlate with post-withdrawal relapse. Given the limited number of relapse events, its predictive value needs further validation in larger prospective cohorts, and it is not recommended for direct clinical risk stratification at present.
关键词
Key words
[Author(id=1330571866088674191, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565360579842171, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=jialanlan89@163.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330571866151588754, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565360579842171, authorId=1330571866088674191, language=EN, stringName=Lanlan JIA, firstName=Lanlan, middleName=null, lastName=JIA, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Rheumatology and Immunology, the First Affiliated Hospital of Wannan Medical University, Wuhu 241000, Anhui, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330571866218697620, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565360579842171, authorId=1330571866088674191, language=CN, stringName=贾兰兰, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=皖南医科大学第一附属医院 风湿免疫科,芜湖 241000,安徽, bio={"content":"贾兰兰,女,硕士,主治医师,研究方向:风湿免疫疾病。E-mail:jialanlan89@163.com
"}, bioImg=null, bioContent=贾兰兰,女,硕士,主治医师,研究方向:风湿免疫疾病。E-mail:jialanlan89@163.com
, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330571866017371018, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565360579842171, xref=null, ext=[AuthorCompanyExt(id=1330571866029953932, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565360579842171, companyId=1330571866017371018, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Rheumatology and Immunology, the First Affiliated Hospital of Wannan Medical University, Wuhu 241000, Anhui, China), AuthorCompanyExt(id=1330571866046731148, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565360579842171, companyId=1330571866017371018, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=皖南医科大学第一附属医院 风湿免疫科,芜湖 241000,安徽)])]), Author(id=1330571866264834966, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565360579842171, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330571866323555225, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565360579842171, authorId=1330571866264834966, language=EN, stringName=Dandan FENG, firstName=Dandan, middleName=null, lastName=FENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Rheumatology and Immunology, the First Affiliated Hospital of Wannan Medical University, Wuhu 241000, Anhui, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330571866369692571, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565360579842171, authorId=1330571866264834966, language=CN, stringName=冯丹丹, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=皖南医科大学第一附属医院 风湿免疫科,芜湖 241000,安徽, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330571866017371018, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565360579842171, xref=null, ext=[AuthorCompanyExt(id=1330571866029953932, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565360579842171, companyId=1330571866017371018, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Rheumatology and Immunology, the First Affiliated Hospital of Wannan Medical University, Wuhu 241000, Anhui, China), AuthorCompanyExt(id=1330571866046731148, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565360579842171, companyId=1330571866017371018, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=皖南医科大学第一附属医院 风湿免疫科,芜湖 241000,安徽)])]), Author(id=1330571866415829917, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565360579842171, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1330571866474550176, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565360579842171, authorId=1330571866415829917, language=EN, stringName=Xiaowan WANG, firstName=Xiaowan, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Rheumatology and Immunology, the First Affiliated Hospital of Wannan Medical University, Wuhu 241000, Anhui, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330571866520687522, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565360579842171, authorId=1330571866415829917, language=CN, stringName=汪筱莞, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=皖南医科大学第一附属医院 风湿免疫科,芜湖 241000,安徽, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330571866017371018, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565360579842171, xref=null, ext=[AuthorCompanyExt(id=1330571866029953932, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565360579842171, companyId=1330571866017371018, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Rheumatology and Immunology, the First Affiliated Hospital of Wannan Medical University, Wuhu 241000, Anhui, China), AuthorCompanyExt(id=1330571866046731148, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565360579842171, companyId=1330571866017371018, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=皖南医科大学第一附属医院 风湿免疫科,芜湖 241000,安徽)])]), Author(id=1330571866566824868, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565360579842171, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=xuliang_57@sohu.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1330571866625545127, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565360579842171, authorId=1330571866566824868, language=EN, stringName=Liang XU, firstName=Liang, middleName=null, lastName=XU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Rheumatology and Immunology, the First Affiliated Hospital of Wannan Medical University, Wuhu 241000, Anhui, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1330571866671682473, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565360579842171, authorId=1330571866566824868, language=CN, stringName=徐亮, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=皖南医科大学第一附属医院 风湿免疫科,芜湖 241000,安徽, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1330571866017371018, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565360579842171, xref=null, ext=[AuthorCompanyExt(id=1330571866029953932, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565360579842171, companyId=1330571866017371018, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Rheumatology and Immunology, the First Affiliated Hospital of Wannan Medical University, Wuhu 241000, Anhui, China), AuthorCompanyExt(id=1330571866046731148, tenantId=1045748351789510663, journalId=1155139928303341788, articleId=1330565360579842171, companyId=1330571866017371018, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=皖南医科大学第一附属医院 风湿免疫科,芜湖 241000,安徽)])])]
贾兰兰,冯丹丹,汪筱莞,徐亮.
孤立性风湿性多肌痛治疗缓解后减停糖皮质激素及转归的单中心回顾性研究[J].
中国临床药理学与治疗学, 2026, 31(10): 1385-1391 DOI:10.12092/j.issn.1009-2501.2026.10.009
| [1] |
Dejaco C, Kerschbaumer A, Aletaha D, et al. Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica[J].Ann Rheum Dis, 2024, 83(1): 48-57.
|
| [2] |
Tomelleri A, van der Geest KSM, Khurshid MA, et al. Disease stratification in GCA and PMR: state of the art and future perspectives[J].Nat Rev Rheumatol, 2023, 19(7): 446-459.
|
| [3] |
Dasgupta B, Cimmino MA, Kremers HM, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative[J].Ann Rheum Dis, 2012, 71(4): 484-492.
|
| [4] |
Harkins P, Cowley S, Burke E, et al. Modern management of isolated polymyalgia rheumatica[J].Rheumatol Ther, 2025, 12(6): 1017-1041.
|
| [5] |
Dejaco C, Singh YP, Perel P, et al. 2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative[J].Arthritis Rheumatol, 2015, 67(10): 2569-2580.
|
| [6] |
Leeb BF, Bird HA.A disease activity score for polymyalgia rheumatica[J].Ann Rheum Dis, 2004, 63(10): 1279-1283.
|
| [7] |
Leeb BF, Rintelen B, Sautner J, et al. The polymyalgia rheumatica activity score in daily use: proposal for a definition of remission[J].Arthritis Rheum, 2007, 57(5): 810-815.
|
| [8] |
Giollo A, Rossini M, Bettili F, et al. Permanent discontinuation of glucocorticoids in polymyalgia rheumatica is uncommon but may be enhanced by amino bisphosphonates[J].J Rheumatol, 2019, 46(3): 318-322.
|
| [9] |
Iorio L, Bond M, Padoan R, et al. Advances in the treatment of polymyalgia rheumatica[J].Rheumatology (Oxford), 2025, 64(Suppl 1): i48-i54.
|
| [10] |
Nazarinia A, Moghimi J, Toussi J.Efficacy of methotrexate in patients with polymyalgia rheumatica[J].Koomesh, 2012, 14(3): 265-270.
|
| [11] |
Aoki A, Kobayashi H, Yamaguchi Y. Predictors of long-term therapy with glucocorticoid in polymyalgia rheumatica[J].Mod Rheumatol, 2021, 31(2): 417-420.
|
| [12] |
Muratore F, Pipitone N, Hunder GG, et al. Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis[J].Clin Exp Rheumatol, 2013, 31(4): S86-S92.
|
| [13] |
Floris A, Piga M, Chessa E, et al. Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis[J].Clin Rheumatol, 2022, 41(1): 19-31.
|
| [14] |
Rahimi M, Esalatmanesh K, Daneshvar S, et al. Outcomes of polymyalgia rheumatica in real-world practice: a longitudinal cohort study[J].Rom J Intern Med, 2024, 62(3): 286-294.
|
| [15] |
Dejaco C, Matteson EL.Polymyalgia rheumatica[J].N Engl J Med, 2026, 394(11): 1097-1109.
|
| [16] |
Ricordi C, Pipitone N, Marvisi C, et al. Steroid-sparing agents in polymyalgia rheumatica: how will they fit into the treatment paradigm?[J].Expert Rev Clin Immunol, 2023, 19(10): 1195-1203.
|
| [17] |
Dejaco C, Singh YP, Perel P, et al. Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica[J].Ann Rheum Dis, 2015, 74(10): 1808-1817.
|
| [18] |
Yates M, Watts RA, Swords F, et al. Glucocorticoid withdrawal in polymyalgia rheumatica: the theory versus the practice[J].Clin Exp Rheumatol, 2017, 35(1): 1-2.
|
| [19] |
Mangoni AA, Zinellu A.Diagnostic accuracy of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in rheumatoid arthritis: a systematic review and meta-analysis[J].Clin Exp Med, 2024, 24(1): 207-220.
|
| [20] |
Carrión-Barberà I, Lood C, Stultz RD, et al. Diagnostic and prognostic utility of complete blood count-derived ratios in giant cell arteritis: a retrospective fast-track clinic cohort study[J].Rheumatol Int, 2025, 45(12): 2761-2769.
|
| [21] |
Yu R, Zhang L, Zhang J, et al. The diagnostic and prognostic role of novel biomarkers in anti-neutrophil cytoplasmic antibody-associated vasculitis[J].Front Immunol, 2025, 16: 1588287.
|
| [22] |
Koster MJ, Warrington KJ. Giant cell arteritis: pathogenic mechanisms and new potential therapeutic targets[J].BMC Rheumatol, 2017, 1(1): 2.
|
| [23] |
Yu R, Miao M, Li S, et al. The clinical characteristics and significance of novel inflammatory biomarkers in patients with polymyalgia rheumatica: a single-center study from China[J].Cytokine, 2025, 192: 156953.
|
| [24] |
Jung JY, Lee E, Suh CH, et al. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are associated with disease activity in polymyalgia rheumatica[J].J Clin Lab Anal, 2019, 33(9): e23000.
|
基金资助
芜湖市科技民生专项(2020ms3-4)
中国临床试验注册研究(ChiCTR1800019715)